- Home
- BUR vs KURA Comparison
BUR vs KURA Comparison
Compare BUR & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUR | KURA |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BUR | KURA |
|---|---|---|
| Price | $4.10 | $11.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $13.58 | ★ $25.56 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $413,360,000.00 | $67,482,000.00 |
| Revenue This Year | $104.62 | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $3.59 | $7.36 |
| 52 Week High | $13.07 | $13.90 |
Technical Indicators
Market Signals| Indicator | BUR | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 44.23 |
| Support Level | $4.13 | $8.45 |
| Resistance Level | $4.49 | $11.40 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 22.89 | 10.44 |
Price Performance
Historical ComparisonAbout BUR Burford Capital Limited
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.